PMID- 35948984
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20230322
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Aug 10
TI  - Cytomegalovirus infection is a risk factor for venous thromboembolism in 
      ANCA-associated vasculitis.
PG  - 192
LID - 10.1186/s13075-022-02879-7 [doi]
LID - 192
AB  - BACKGROUND: Venous thromboembolism (VTE) is a common complication in patients 
      with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) and 
      confers significant morbidity and mortality. Both acute and past cytomegalovirus 
      (CMV) infection have been identified as risk factors for VTE in immunocompetent 
      and immunosuppressed individuals. Here, we examine whether past exposure to CMV 
      is a risk factor for VTE amongst patients with AAV. METHODS: We retrospectively 
      analysed outcomes of patients with a new diagnosis of AAV from a UK cohort. All 
      confirmed cases of VTE where CMV IgG serology was available were recorded. 
      Retrospective collection of the same data for patients at a North American centre 
      was used as a validation cohort. RESULTS: VTE was common with 12% of patients 
      from the study cohort (total 259 patients) developing an event during the median 
      follow-up period of 8.5 years of which 60% occurred within the first 12 months 
      following diagnosis. Sixteen percent of CMV seropositive patients developed a VTE 
      compared with 5% of patients who were seronegative (p = 0.007) and CMV 
      seropositivity remained an independent predictor of VTE in multivariable analysis 
      (HR 2.96 [1.094-8.011] p = 0.033). CMV seropositivity at diagnosis was confirmed 
      as a significant risk factor for VTE in the American validation cohort (p = 
      0.032). CONCLUSIONS: VTE is common in patients with AAV, especially within the 
      first year of diagnosis. Past infection with CMV is an independent risk factor 
      associated with VTE in AAV.
CI  - (c) 2022. The Author(s).
FAU - King, C
AU  - King C
AUID- ORCID: 0000-0001-8918-0404
AD  - Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals 
      Birmingham, Birmingham, UK. catherine.king4@nhs.net.
AD  - Institute of Immunology and Immunotherapy, University of Birmingham, Cancer 
      Sciences Building, Edgbaston, Birmingham, B15 2TT, UK. catherine.king4@nhs.net.
FAU - Patel, R
AU  - Patel R
AD  - Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals 
      Birmingham, Birmingham, UK.
FAU - Mendoza, C
AU  - Mendoza C
AD  - University of North Carolina Gillings School of Global Public Health, Chapel 
      Hill, NC, USA.
FAU - Walker, J K
AU  - Walker JK
AD  - Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals 
      Birmingham, Birmingham, UK.
FAU - Wu, E Y
AU  - Wu EY
AD  - University of North Carolina Pediatric Allergy, Immunology, and Rheumatology, 
      Chapel Hill, USA.
FAU - Moss, P
AU  - Moss P
AD  - Institute of Immunology and Immunotherapy, University of Birmingham, Cancer 
      Sciences Building, Edgbaston, Birmingham, B15 2TT, UK.
FAU - Morgan, M D
AU  - Morgan MD
AD  - Hull York Medical School, University of Hull, Hull, UK.
FAU - O'Dell Bunch, D
AU  - O'Dell Bunch D
AD  - University of North Carolina Department of Medicine, Kidney Centre, Chapel Hill, 
      NC, USA.
FAU - Harper, L
AU  - Harper L
AD  - Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals 
      Birmingham, Birmingham, UK.
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Chanouzas, D
AU  - Chanouzas D
AD  - Department of Renal Medicine, Queen Elizabeth Hospital, University Hospitals 
      Birmingham, Birmingham, UK.
AD  - Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
LA  - eng
GR  - MR/R011230/1/MRC_/Medical Research Council/United Kingdom
GR  - P01 DK058335/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20220810
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
MH  - Cytomegalovirus
MH  - *Cytomegalovirus Infections/complications/diagnosis/epidemiology
MH  - Humans
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Venous Thromboembolism/diagnosis/epidemiology/etiology
PMC - PMC9364516
OTO - NOTNLM
OT  - ANCA
OT  - Cytomegalovirus
OT  - Thrombosis
OT  - Vasculitis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/11 06:00
MHDA- 2022/08/13 06:00
PMCR- 2022/08/10
CRDT- 2022/08/10 23:40
PHST- 2022/02/08 00:00 [received]
PHST- 2022/07/24 00:00 [accepted]
PHST- 2022/08/10 23:40 [entrez]
PHST- 2022/08/11 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/08/10 00:00 [pmc-release]
AID - 10.1186/s13075-022-02879-7 [pii]
AID - 2879 [pii]
AID - 10.1186/s13075-022-02879-7 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2022 Aug 10;24(1):192. doi: 10.1186/s13075-022-02879-7.